Clinical Trial Update: SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia [Phase 4]

View source ↗

Summary

Phase 4 trial updating SD-OCT-guided intravitreal ranibizumab treatment for choroidal neovascularization due to myopia and age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Vista Klinik | Conditions: Choroidal Neovascularization, Age Related Macular Degeneration | Phase 4 | Status: COMPLETED